Abstract:Background: Furosemide is a commonly used loop diuretic in critical care. However, its effect on the progression of oliguric acute kidney injury across different central venous pressure (CVP) remains unknown. This study therefore aims to investigate the association between furosemide(6-12h ) (defined as the use of furosemide within 6 h after the diagnosis of AKI according to the urine output [UO] criteria set by the Kidney Disease: Improving Global Outcomes [KDIGO] guidelines) and the progression of AKI across different CVP6-12h (defined as CVP within 6 h after the diagnosis of AKI by the KDIGO UO criteria) levels. Methods: Patients involved in this study were identified from the Medical Information Mart for Intensive Care IV database with the following criteria: (i) adults with UO < 0.5 mL/kg per hour for the first 6 h upon admission to the intensive care unit (ICU) (meeting stage 1 AKI by UO) and (ii) CVP6-12h ranging from 0 to 30 mm Hg. From there on, the target primary outcome would be progression to stage 3 AKI by UO among these chosen patients. The secondary outcome was 28-d mortality since ICU admission. The risks of severe-stage AKI progression and 28-d mortality were respectively examined against furosemide(6-12h ) (vs. without furosemide6-12h) within the full cohort and across different subgroups of CV6-12h , using multivariate adjusted logistic regression and inverse probability treatment weighting (IPTW). Sensitivity analyses were performed to assess the robustness of our findings. Results: One thousand one hundred eighty patients were ultimately selected for this study, of whom 643 (54.5%) progressed to stage 3 AKI from stage 1 based on the UO criteria by KDIGO. Multivariate analysis showed that furosemide(6-12h ) is significantly associated with this severe-stage progression within the full cohort (odds ratio [OR] was 0.62 at 95% confidence interval [CI] of 0.43-0.90, P = 0.011). After dividing the patients into CVP6-12h subgroups according to their CVP during the early phases, lower risk of AKI progression was observed only in furosemide(6-12h ) application at CVP6-12h of > 12 mm Hg (adjusted OR was 0.40 at 95% CI of 0.25-0.65, P < 0.001), as confirmed by the IPTW analysis (OR was 0.47 at 95% CI of 0.29-0.76, P = 0.002). The robustness of these findings was confirmed by sensitivity analyses. In addition, for patients with CVP6-12h > 12 mm Hg, furosemide(6-12h ) is also significantly associated with lower risk of 28-d mortality (adjusted OR was 0.47 at 95% CI of 0.25-0.92, P = 0.026) in the multivariate logistic regression analysis, and there was a similar trend in the IPTW analysis (adjusted OR was 0.55 at 95% CI of 0.28-1.10, P = 0.092). Conclusions: Among the identified early-stage AKI patients in critical care, the use of furosemide was associated only with lower risk of oliguric AKI progression and 28-d mortality within the high CVP group. These findings suggest the potential of CVP as a guidance or reference point in the usage of furosemide among early-stage oliguric AKI patients in the ICU.

Role of the Furosemide Stress Test in Renal Injury Prognosis

Furosemide stress test as a predictive marker of acute kidney injury progression or renal replacement therapy: a systemic review and meta-analysis

The furosemide stress test: current use and future potential

Furosemide stress test and interstitial fibrosis in kidney biopsies in chronic kidney disease

The furosemide stress test predicts the timing of continuous renal replacement therapy initiation in critically ill patients with acute kidney injury: a double-blind prospective intervention cohort study

Furosemide stress test to predict acute kidney injury progression in critically ill children

The furosemide stress test predicts successful discontinuation of continuous renal replacement therapy in critically ill patients with acute kidney injury

Early versus standard initiation of renal replacement therapy in furosemide stress test non-responsive acute kidney injury patients (the FST trial)

[New kidney function tests: Renal functional reserve and furosemide stress test]

Furosemide Stress Test as a Predicting Biomarker for Delayed Graft Function in Kidney Transplantation

Predicting the Development of Renal Replacement Therapy Indications by Combining the Furosemide Stress Test and Chemokine (C-C Motif) Ligand 14 in a Cohort of Postsurgical Patients

Predictive enrichment for the need of renal replacement in sepsis-associated acute kidney injury: combination of furosemide stress test and urinary biomarkers TIMP-2 and IGFBP-7

Association Between Furosemide Administration and Outcomes in Critically Ill Patients with Acute Kidney Injury.

Furosemide attenuates tubulointerstitial injury and allows functional testing of porcine kidneys during normothermic machine perfusion

Prospective assessment of the impact of intraoperative diuretics in kidney transplant recipient surgery

The dynamics of urine sodium concentration after intra-venous furosemide in patients with acute heart failure

Diuretic Use in Post-Kidney Transplant Patients: A Retrospective Chart Review

The effects of early-phase furosemide use on the progression of oliguric acute kidney injury across different central venous pressure: a retrospective analysis

Furosemide responsiveness predicts acute kidney injury progression after cardiac surgery

Hospitalized patients received furosemide undergoing acute kidney injury: the risk and prediction tool

#3937 URINARY EXCRETION OF LIVER-TYPE FATTY ACID-BINDING PROTEIN DETECTS KIDNEY HISTOLOGICAL ALTERATIONS DURING PROGRESSIVE RENAL FIBROSIS